{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -2.7149339, "regularMarketPrice": 43.0, "exchange": "FRA", "shortName": "ULTRAGENYX PHARM. DL-,001", "longName": "Ultragenyx Pharmaceutical Inc.", "messageBoardId": "finmb_117471985", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketTime": 1683871215, "earningsTimestamp": 1683234000, "earningsTimestampStart": 1690369140, "earningsTimestampEnd": 1690804800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -9.66, "epsForward": -5.74, "epsCurrentYear": -6.65, "priceEpsCurrentYear": -6.4661655, "sharesOutstanding": 70814496, "bookValue": 3.121, "fiftyDayAverage": 38.152, "fiftyDayAverageChange": 4.8479996, "fiftyDayAverageChangePercent": 0.12707065, "twoHundredDayAverage": 41.1675, "twoHundredDayAverageChange": 1.8325005, "twoHundredDayAverageChangePercent": 0.04451328, "marketCap": 3045023232, "forwardPE": -7.4912896, "priceToBook": 13.777636, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1412575200000, "priceHint": 2, "regularMarketChange": -1.2000008, "regularMarketDayHigh": 43.0, "regularMarketDayRange": "43.0 - 43.0", "regularMarketDayLow": 43.0, "regularMarketVolume": 130, "regularMarketPreviousClose": 44.2, "bid": 43.2, "ask": 43.6, "bidSize": 1000, "askSize": 1000, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 43.0, "averageDailyVolume3Month": 11, "averageDailyVolume10Day": 27, "fiftyTwoWeekLowChange": 10.0, "fiftyTwoWeekLowChangePercent": 0.3030303, "fiftyTwoWeekRange": "33.0 - 65.5", "fiftyTwoWeekHighChange": -22.5, "fiftyTwoWeekHighChangePercent": -0.34351146, "fiftyTwoWeekLow": 33.0, "fiftyTwoWeekHigh": 65.5, "symbol": "UP0.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "60 Leveroni Court", "city": "Novato", "state": "CA", "zip": "94949", "country": "United States", "phone": "415 483 8800", "website": "https://www.ultragenyx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.", "fullTimeEmployees": 1311, "companyOfficers": [{"maxAge": 1, "name": "Dr. Emil D. Kakkis M.D., Ph.D.", "age": 62, "title": "Founder, Pres, CEO & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 1366354, "fmt": "1.37M", "longFmt": "1,366,354"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1888758, "fmt": "1.89M", "longFmt": "1,888,758"}}, {"maxAge": 1, "name": "Mr. John Richard Pinion II", "age": 56, "title": "Chief Quality Operations Officer & Exec. VP of Translational Sciences", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 806193, "fmt": "806.19k", "longFmt": "806,193"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Erik  Harris", "age": 51, "title": "Exec. VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 848237, "fmt": "848.24k", "longFmt": "848,237"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Theodore A. Huizenga", "age": 51, "title": "Sr. VP, Corp. Controller & Principal Accounting Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dennis Karl Huang", "age": 57, "title": "Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP", "yearBorn": 1965, "fiscalYear": 2015, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Danielle  Keatley", "title": "Sr. Director of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Karah Herdman Parschauer J.D.", "age": 44, "title": "Chief Legal Officer & Exec. VP", "yearBorn": 1978, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ernie W. Meyer", "age": 58, "title": "Chief HR Officer & Exec. VP", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Thomas R. Kassberg", "age": 62, "title": "Chief Bus. Officer & Exec. VP", "yearBorn": 1960, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cordelia  Leonard", "age": 62, "title": "Sr. VP of Regulatory Affairs", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 1, "compensationRisk": 4, "shareHolderRightsRisk": 7, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}